Obsidian Therapeutics, Inc.

Overview

Compare with another stock.

• TickerOBX on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersCambridge, Massachusetts¹
• Business address1030 Massachusetts Avenue, Cambridge, Ma 02138²
• Filer categoryNon-accelerated filer, Emerging growth company²

See how the biggest companies compare on our leaderboards

Corporate structure

Obsidian Therapeutics, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Obsidian Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerMadan Jagasia Aug 3, 2026 to now³
• Chief financial officerJulie B. Feder Aug 3, 2026 to now⁴

Former names

• Gazelle Parent, Inc.Apr 22, 2026 to Aug 3, 2026²

Timeline

1. Aug 14, 20268-K Financial statements and exhibits¹⁰
2. Aug 3, 2026New chief executive Madan Jagasia becomes CEO³
3. Aug 3, 20268-K Entered a material agreement; Completed an acquisition or sale; Results of operations¹¹

Calendar

When it reported results

1. Aug 3, 2026Reported quarterly or annual results¹¹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

35 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 14 insider forms, 5 large holders, 13 other. The latest 20:

1. Oct 5, 2026SCHEDULE 13G EDGAR
2. Sep 9, 2026EFFECT EDGAR
3. Aug 28, 2026S-1 EDGAR
4. Aug 14, 20268-K/A EDGAR
5. Aug 14, 202610-Q EDGAR
6. Aug 11, 2026SCHEDULE 13G EDGAR
7. Aug 10, 2026SCHEDULE 13G EDGAR
8. Aug 10, 2026SCHEDULE 13G EDGAR
9. Aug 10, 2026SCHEDULE 13G EDGAR
10. Aug 5, 20264 EDGAR
11. Aug 5, 20264 EDGAR
12. Aug 5, 20264 EDGAR
13. Aug 5, 20264 EDGAR
14. Aug 5, 20264 EDGAR
15. Aug 5, 20264 EDGAR
16. Aug 3, 2026CERT EDGAR
17. Aug 3, 20263 EDGAR
18. Aug 3, 20263 EDGAR
19. Aug 3, 20263 EDGAR
20. Aug 3, 20263 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Paradigm Biocapital Advisors LPSCHEDULE 13G, 1 filing Oct 5, 2026¹²
• Deep Track Capital, LPSCHEDULE 13G, 1 filing Aug 11, 2026¹³
• Atlas Venture Fund X, L.P.SCHEDULE 13G, 1 filing Aug 10, 2026¹⁴
• Novo Holdings A/SSCHEDULE 13G, 1 filing Aug 10, 2026¹⁵
• RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G, 1 filing Aug 10, 2026¹⁶

SEC filer profile

How Obsidian Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARObsidian Therapeutics, Inc.¹
• CIK0002130606
• Employer ID (EIN)42-1977778¹
• Filer statusNon-accelerated filer<br>emerging growth company¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address1030 Massachusetts Avenue, Cambridge, MA 02138¹
• Phone(781) 806-6245¹
• Shares outstanding61,772,876 as of Aug 10, 2026¹⁷
• On EDGAR sinceApr 22, 2026¹
• Filings35 in all: 3 (8), 4 (6), SCHEDULE 13G (5), S-4/A (4), EFFECT (2), 10-Q (1), 424B3 (1), 8-A12B (1)¹
  All 15 form types

  8-A12B/A (1), 8-K (1), 8-K/A (1), CERT (1), S-1 (1), S-4 (1), S-8 (1)

• Latest filingsQuarterly report (10-Q) Aug 14, 2026
  Latest 8-K (8-K) Aug 3, 2026